AIMC Topic: Drug Discovery

Clear Filters Showing 701 to 710 of 1558 articles

Compound-protein interaction prediction by deep learning: Databases, descriptors and models.

Drug discovery today
The screening of compound-protein interactions (CPIs) is one of the most crucial steps in finding hit and lead compounds. Deep learning (DL) methods for CPI prediction can address intrinsic limitations of traditional HTS and virtual screening with th...

Accurate Physical Property Predictions via Deep Learning.

Molecules (Basel, Switzerland)
Neural networks and deep learning have been successfully applied to tackle problems in drug discovery with increasing accuracy over time. There are still many challenges and opportunities to improve molecular property predictions with satisfactory ac...

DeepFusion: A deep learning based multi-scale feature fusion method for predicting drug-target interactions.

Methods (San Diego, Calif.)
Predicting drug-target interactions (DTIs) is essential for both drug discovery and drug repositioning. Recently, deep learning methods have achieved relatively significant performance in predicting DTIs. Generally, it needs a large amount of approve...

Defining clinical outcome pathways.

Drug discovery today
Here, we propose a broad concept of 'Clinical Outcome Pathways' (COPs), which are defined as a series of key molecular and cellular events that underlie therapeutic effects of drug molecules. We formalize COPs as a chain of the following events: mole...

A deep-learning system bridging molecule structure and biomedical text with comprehension comparable to human professionals.

Nature communications
To accelerate biomedical research process, deep-learning systems are developed to automatically acquire knowledge about molecule entities by reading large-scale biomedical data. Inspired by humans that learn deep molecule knowledge from versatile rea...

m6A modification: recent advances, anticancer targeted drug discovery and beyond.

Molecular cancer
Abnormal N6-methyladenosine (m6A) modification is closely associated with the occurrence, development, progression and prognosis of cancer, and aberrant m6A regulators have been identified as novel anticancer drug targets. Both traditional medicine-r...

Machine learning modeling of family wide enzyme-substrate specificity screens.

PLoS computational biology
Biocatalysis is a promising approach to sustainably synthesize pharmaceuticals, complex natural products, and commodity chemicals at scale. However, the adoption of biocatalysis is limited by our ability to select enzymes that will catalyze their nat...

Artificial intelligence-enabled virtual screening of ultra-large chemical libraries with deep docking.

Nature protocols
With the recent explosion of chemical libraries beyond a billion molecules, more efficient virtual screening approaches are needed. The Deep Docking (DD) platform enables up to 100-fold acceleration of structure-based virtual screening by docking onl...

SPP-CPI: Predicting Compound-Protein Interactions Based On Neural Networks.

IEEE/ACM transactions on computational biology and bioinformatics
Identifying interactions between compound and protein is a substantial part of the drug discovery process. Accurate prediction of interaction relationships can greatly reduce the time of drug development. The uniqueness of our method lies in three as...